Isomorphic Labs raises $2B+ funding

AI drug discovery is back in the funding spotlight — and this time the number is huge. Isomorphic Labs, the Google DeepMind spinout building models for drug design, is in advanced talks to raise more than $2 billion. If it closes anywhere near that size, it would be one of the biggest private financings yet for an AI-first biotech platform. (bloomberg.com) ### What is Isomorphic Labs, exactly? Isomorphic Labs is the Alphabet-backed company created out of DeepMind’s biology work. (bloomberg.com) Its pitch is simple to say but hard to do: use frontier AI not just to predict biology, but to help invent actual medicines faster and more reliably. The company has tied its identity closely to AlphaFold and the broader idea of “digital biology” — turning messy lab problems into model-driven ones. ### Why is $2 billion such a big deal? Because this is not normal biotech financing. Drug discovery companies burn money across wet labs, compute, data, and long hiring cycles before they get anything close to a marketable drug. A round above $2 billion says investors are willing to fund Isomorphic less like a narrow biotech bet and more like a full-stack platform company that needs years of infrastructure and scientific buildout. (bloomberg.com) ### Who is backing it? The reported lead is Thrive Capital — the same firm that led Isomorphic Labs’ first outside round. Back on March 31, 2025, Isomorphic announced a $600 million financing led by Thrive, with participation from GV and follow-on capital from Alphabet. (isomorphiclabs.com) Bloomberg now says Thrive is set to lead again, and Alphabet is also expected to join this new round. ### Why would investors keep doubling down? Basically, the dream here is enormous. If AI can improve hit-finding, molecular design, and the odds that a candidate survives the long handoff into development, the payoff is not just one drug. It is a machine for making drugs. That is why investors tolerate the long timelines — the upside looks like software-scale leverage applied to pharma’s most expensive bottleneck. (bloomberg.com) This is also why AlphaFold mattered so much: it made the idea of model-native biology feel less speculative. ### But hasn’t AI drug discovery been hyped before? Yes — and that is the catch. A lot of companies can show slick demos, partnerships, or promising molecules on slides. Much fewer can prove that AI meaningfully changes clinical outcomes or development speed at scale. (isomorphiclabs.com) So this financing is not proof the model works all the way through. It is proof that top investors still think Isomorphic has a better shot than most at crossing that gap. ### What has Isomorphic done lately? The company has been broadening its pharma footprint. Its announcements page shows a Johnson & Johnson research collaboration in January 2026, following earlier collaboration activity and expansion news in 2025. That matters because these partnerships do two jobs at once — they validate demand from big drugmakers and they give Isomorphic more shots on goal across different disease areas and modalities. (blog.google) ### So what changed this week? The new thing is scale. A year ago, outside investors put in $600 million. Now Isomorphic is discussing a round worth more than three times that amount. Even if terms change before closing, the signal is clear: the market is treating AI drug discovery as one of the few biotech-adjacent categories that can still pull mega-round capital. (bloomberg.com) ### Bottom line? This is a financing story, but really it is a conviction story. Investors are betting that the company born from DeepMind’s biology work can turn breakthrough models into an industrial drug engine. The money does not settle that question — but it gives Isomorphic a lot more runway to try. (bloomberg.com) (isomorphiclabs.com 1) (isomorphiclabs.com 2)